These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

164 related items for PubMed ID: 27997350

  • 1. A low dose (6.5 mg) of intravaginal DHEA permits a strictly local action while maintaining all serum estrogens or androgens as well as their metabolites within normal values.
    Labrie F, Martel C.
    Horm Mol Biol Clin Investig; 2017 Feb 01; 29(2):39-60. PubMed ID: 27997350
    [Abstract] [Full Text] [Related]

  • 2. Intravaginal prasterone (DHEA) provides local action without clinically significant changes in serum concentrations of estrogens or androgens.
    Labrie F, Martel C, Bérubé R, Côté I, Labrie C, Cusan L, Gomez JL.
    J Steroid Biochem Mol Biol; 2013 Nov 01; 138():359-67. PubMed ID: 23954500
    [Abstract] [Full Text] [Related]

  • 3. Serum levels of sex steroids and metabolites following 12 weeks of intravaginal 0.50% DHEA administration.
    Ke Y, Labrie F, Gonthier R, Simard JN, Bergeron D, Martel C, Vaillancourt M, Montesino M, Lavoie L, Archer DF, Balser J, Moyneur E, other participating Members of the Prasterone Clinical Research Group.
    J Steroid Biochem Mol Biol; 2015 Nov 01; 154():186-96. PubMed ID: 26291918
    [Abstract] [Full Text] [Related]

  • 4. Serum steroid concentrations remain within normal postmenopausal values in women receiving daily 6.5mg intravaginal prasterone for 12 weeks.
    Martel C, Labrie F, Archer DF, Ke Y, Gonthier R, Simard JN, Lavoie L, Vaillancourt M, Montesino M, Balser J, Moyneur É, other participating members of the Prasterone Clinical Research Group.
    J Steroid Biochem Mol Biol; 2016 May 01; 159():142-53. PubMed ID: 26972555
    [Abstract] [Full Text] [Related]

  • 5. Physiological changes in dehydroepiandrosterone are not reflected by serum levels of active androgens and estrogens but of their metabolites: intracrinology.
    Labrie F, Bélanger A, Cusan L, Candas B.
    J Clin Endocrinol Metab; 1997 Aug 01; 82(8):2403-9. PubMed ID: 9253308
    [Abstract] [Full Text] [Related]

  • 6. Science of intracrinology in postmenopausal women.
    Labrie F, Bélanger A, Pelletier G, Martel C, Archer DF, Utian WH.
    Menopause; 2017 Jun 01; 24(6):702-712. PubMed ID: 28098598
    [Abstract] [Full Text] [Related]

  • 7. Serum steroids remain within the same normal postmenopausal values during 12-month intravaginal 0.50% DHEA.
    Ke Y, Gonthier R, Simard JN, Archer D, Lavoie L, Martel C, Vaillancourt M, Labrie F.
    Horm Mol Biol Clin Investig; 2015 Dec 01; 24(3):117-29. PubMed ID: 26509785
    [Abstract] [Full Text] [Related]

  • 8. Efficacy of intravaginal dehydroepiandrosterone (DHEA) on moderate to severe dyspareunia and vaginal dryness, symptoms of vulvovaginal atrophy, and of the genitourinary syndrome of menopause.
    Labrie F, Archer DF, Koltun W, Vachon A, Young D, Frenette L, Portman D, Montesino M, Côté I, Parent J, Lavoie L, BSc AB, Martel C, Vaillancourt M, Balser J, Moyneur É, members of the VVA Prasterone Research Group.
    Menopause; 2018 Nov 01; 25(11):1339-1353. PubMed ID: 30358731
    [Abstract] [Full Text] [Related]

  • 9. All sex steroids are made intracellularly in peripheral tissues by the mechanisms of intracrinology after menopause.
    Labrie F.
    J Steroid Biochem Mol Biol; 2015 Jan 01; 145():133-8. PubMed ID: 24923731
    [Abstract] [Full Text] [Related]

  • 10. Serum steroid levels during 12-week intravaginal dehydroepiandrosterone administration.
    Labrie F, Archer D, Bouchard C, Fortier M, Cusan L, Gomez JL, Girard G, Baron M, Ayotte N, Moreau M, Dubé R, Côté I, Labrie C, Lavoie L, Bérubé R, Bélanger P, Berger L, Gilbert L, Martel C, Balser J.
    Menopause; 2009 Jan 01; 16(5):897-906. PubMed ID: 19436226
    [Abstract] [Full Text] [Related]

  • 11. Lack of effect of intravaginal dehydroepiandrosterone (DHEA, prasterone) on the endometrium in postmenopausal women.
    Portman DJ, Labrie F, Archer DF, Bouchard C, Cusan L, Girard G, Ayotte N, Koltun W, Blouin F, Young D, Wade A, Martel C, Dubé R, other participating members of VVA Prasterone Group.
    Menopause; 2015 Dec 01; 22(12):1289-95. PubMed ID: 25968836
    [Abstract] [Full Text] [Related]

  • 12. Bioavailability and metabolism of oral and percutaneous dehydroepiandrosterone in postmenopausal women.
    Labrie F, Bélanger A, Labrie C, Candas B, Cusan L, Gomez JL.
    J Steroid Biochem Mol Biol; 2007 Oct 01; 107(1-2):57-69. PubMed ID: 17627814
    [Abstract] [Full Text] [Related]

  • 13. Lack of influence of dyspareunia on the beneficial effect of intravaginal prasterone (dehydroepiandrosterone, DHEA) on sexual dysfunction in postmenopausal women.
    Labrie F, Archer D, Bouchard C, Fortier M, Cusan L, Gomez JL, Girard G, Baron M, Ayotte N, Moreau M, Dubé R, Côté I, Labrie C, Lavoie L, Gilbert L, Martel C, Balser J.
    J Sex Med; 2014 Jul 01; 11(7):1766-85. PubMed ID: 24774442
    [Abstract] [Full Text] [Related]

  • 14. Effect of intravaginal DHEA on serum DHEA and eleven of its metabolites in postmenopausal women.
    Labrie F, Cusan L, Gomez JL, Côté I, Bérubé R, Bélanger P, Martel C, Labrie C.
    J Steroid Biochem Mol Biol; 2008 Sep 01; 111(3-5):178-94. PubMed ID: 18598765
    [Abstract] [Full Text] [Related]

  • 15. Effect of Intravaginal Prasterone on Sexual Dysfunction in Postmenopausal Women with Vulvovaginal Atrophy.
    Labrie F, Derogatis L, Archer DF, Koltun W, Vachon A, Young D, Frenette L, Portman D, Montesino M, Côté I, Parent J, Lavoie L, Beauregard A, Martel C, Vaillancourt M, Balser J, Moyneur É, Members of the VVA Prasterone Research Group.
    J Sex Med; 2015 Dec 01; 12(12):2401-12. PubMed ID: 26597311
    [Abstract] [Full Text] [Related]

  • 16. Efficacy of intravaginal dehydroepiandrosterone (DHEA) on moderate to severe dyspareunia and vaginal dryness, symptoms of vulvovaginal atrophy, and of the genitourinary syndrome of menopause.
    Labrie F, Archer DF, Koltun W, Vachon A, Young D, Frenette L, Portman D, Montesino M, Côté I, Parent J, Lavoie L, Beauregard A, Martel C, Vaillancourt M, Balser J, Moyneur É, VVA Prasterone Research Group.
    Menopause; 2016 Mar 01; 23(3):243-56. PubMed ID: 26731686
    [Abstract] [Full Text] [Related]

  • 17. Concentration range of serum sex steroids in normal postmenopausal women and those with diagnosis of vulvovaginal atrophy.
    Ke Y, Bélanger A, Simard JN, Gonthier R, Martel C, Vaillancourt M, Labrie F.
    Menopause; 2018 Mar 01; 25(3):293-300. PubMed ID: 29206779
    [Abstract] [Full Text] [Related]

  • 18. A sensitive, simple and robust LC-MS/MS method for the simultaneous quantification of seven androgen- and estrogen-related steroids in postmenopausal serum.
    Ke Y, Bertin J, Gonthier R, Simard JN, Labrie F.
    J Steroid Biochem Mol Biol; 2014 Oct 01; 144 Pt B():523-34. PubMed ID: 25158021
    [Abstract] [Full Text] [Related]

  • 19. Changes in serum DHEA and eleven of its metabolites during 12-month percutaneous administration of DHEA.
    Labrie F, Cusan L, Gomez JL, Martel C, Bérubé R, Bélanger P, Chaussade V, Deloche C, Leclaire J.
    J Steroid Biochem Mol Biol; 2008 May 01; 110(1-2):1-9. PubMed ID: 18359622
    [Abstract] [Full Text] [Related]

  • 20. Androgens in women are essentially made from DHEA in each peripheral tissue according to intracrinology.
    Labrie F, Martel C, Bélanger A, Pelletier G.
    J Steroid Biochem Mol Biol; 2017 Apr 01; 168():9-18. PubMed ID: 28153489
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.